(function(){var loadHandler=window['sl_{DC1F7540-1882-43D0-A075-6AAB30A2CE8C}'];loadHandler&&loadHandler(8, '<div id="spr0_5dc05e4c"><div id="spr1_5dc05e4c" class="kern slide"><img id="img3_5dc05e4c" src="data/img1.png" width="720px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_5dc05e4c" class="kern slide"><img id="img0_5dc05e4c" src="data/img2.png" width="721.48" height="100.8" alt="" style="left:-1.48px;"/><div id="svg1_5dc05e4c" style="left:-1.48px;top:99.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#c76c02" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><div id="svg2_5dc05e4c" style="left:-1.48px;top:0.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#2e3546" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><img id="img1_5dc05e4c" src="data/img3.png" width="721.48" height="43.101" alt="" style="top:496.899px;"/><div id="spr3_5dc05e4c" style="left:657.715px;top:499.855px;"><img id="img2_5dc05e4c" src="data/img4.png" width="56" height="36" alt="CHRC logo_with text.psd" style="left:-0.105px;top:-0.177px;"/></div><div id="spr4_5dc05e4c" style="left:-6.495px;top:20.107px;"><div style="width:0px;"><span id="txt0_5dc05e4c" data-width="164.419922" style="left:277.687px;top:5.644px;">Summary</span></div></div><div id="spr5_5dc05e4c" style="left:25.475px;top:122.084px;"><div style="width:0px;"><span id="txt1_5dc05e4c" class="nokern relpos" style="left:7.2px;top:5.941px;"></span><span id="txt2_5dc05e4c" class="relpos" data-width="538.857422" style="left:20.474px;top:5.253px;">Statin monotherapy may not achieve targets in all</span></div><div style="width:0px;"><span id="txt3_5dc05e4c" data-width="86.176758" style="left:34.2px;top:41.253px;">patients</span></div></div><div id="spr6_5dc05e4c" style="left:25.475px;top:122.084px;"><div style="width:0px;"><span id="txt4_5dc05e4c" class="nokern relpos" style="left:7.2px;top:113.941px;"></span><span id="txt5_5dc05e4c" class="relpos" data-width="452.680664" style="left:20.474px;top:113.253px;">Previous add-ons to statin are suboptimal</span></div></div><div id="spr7_5dc05e4c" style="left:25.475px;top:122.084px;"><div style="width:0px;"><span id="txt6_5dc05e4c" class="nokern relpos" style="left:7.2px;top:185.941px;"></span><span id="txt7_5dc05e4c" class="relpos" data-width="572.988281" style="left:20.474px;top:185.253px;">PCSK9 inhibitors appear to have similar efficacy and</span></div><div style="width:0px;"><span id="txt8_5dc05e4c" data-width="555.234375" style="left:34.2px;top:221.253px;">safety in individuals with and without diabetes (with</span></div><div style="width:0px;"><span id="txt9_5dc05e4c" data-width="575.771484" style="left:34.2px;top:257.253px;">greater absolute risk reduction) and with no apparent</span></div><div style="width:0px;"><span id="txt10_5dc05e4c" data-width="304.980469" style="left:34.2px;top:293.253px;">adverse effects on glycemia</span></div></div></div></div>');})();